NEW YORK, May 11, 2017 /PRNewswire/ --
Stock-Callers.com has initiated coverage on Celsion Corp. (NASDAQ: CLSN), Incyte Corp. (NASDAQ: INCY), ImmunoGen Inc. (NASDAQ: IMGN), and Catabasis Pharmaceuticals Inc. (NASDAQ: CATB). Biotechnology firms are among the most research-intensive organizations in the world. Their product pipelines, a vital component of expansion, are capital intensive. Download the free research reports on these stocks today:
Lawrenceville, New Jersey headquartered Celsion Corp.'s shares gained 0.59%, closing Wednesday's trading session at $0.24. The stock recorded a trading volume of 868,962 shares. The Company's shares are trading 12.34% below their 50-day moving average. Additionally, shares of Celsion, which focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer, have a Relative Strength Index (RSI) of 37.95.
On May 05th, 2017, Celsion announced that it will host a conference call to discuss financial results for the quarter ended March 31st, 2017, and provide an update on its development programs for ThermoDox®, at 11:00 a.m. EDT on Friday, May 12th, 2017. The call will be broadcast live on the Company's website. See our free and comprehensive research report on CLSN at:
On Wednesday, shares in Wilmington, Delaware headquartered Incyte Corp. recorded a trading volume of 1.23 million shares. The stock declined 1.26%, ending the day at $118.22. The Company's shares have advanced 17.90% on an YTD basis. The stock is trading above its 200-day moving average by 9.88%. Furthermore, shares of Incyte, which focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the US and internationally, have an RSI of 30.10.
On April 17th, 2017, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'.
On May 04th, 2017, Incyte reported Q1 2017 financial results. Total revenues for the quarter ended March 31st, 2017 were $384 million compared to $263 million for the same period in 2016. Research and development expenses during Q1 2017 were $408 million; selling, general and administrative expenses were $87 million; net income (loss) was $187 million; and cash, cash equivalents and marketable securities totaled $512 million. INCY free research report PDF is just a click away at:
Waltham, Massachusetts headquartered ImmunoGen Inc.'s stock finished the day 0.25% higher at $3.97 with a total trading volume of 878,326 shares. The Company's shares have advanced 28.90% in the last one month, 68.94% in the previous three months, and 94.61% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.12% and 45.15%, respectively. Additionally, shares of ImmunoGen, which develops targeted anticancer therapeutics, have an RSI of 51.33.
On April 19th, 2017, research firm Leerink Partners upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On May 01st, 2017, ImmunoGen announced that the results from a Phase 1 dose-escalation study evaluating mirvetuximab soravtansine in patients with folate receptor alpha-positive solid tumors were published in the journal Cancer. The previously disclosed data demonstrated encouraging clinical activity and a manageable safety profile for mirvetuximab soravtansine, and informed the dose that was used in Phase 1 expansion cohorts and the ongoing Phase 3 FORWARD I trial of patients with platinum-resistant ovarian cancer. Sign up for your complimentary report on IMGN at:
Shares in Cambridge, Massachusetts-based Catabasis Pharmaceuticals Inc. ended yesterday's session 0.74% higher at $1.37. The stock recorded a trading volume of 250,488 shares. The Company's shares have advanced 10.48% over the previous three months. The stock is trading 5.18% below its 50-day moving average. Moreover, shares of Catabasis Pharmaceuticals have an RSI of 43.46.
On April 27th, 2017, Catabasis Pharma, which focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the US, announced that it will report Q1 2017 financial results after the NASDAQ Global Market close on Thursday, May 11th, 2017. Jill C. Milne, Ph.D., CEO, will host a conference call and webcast at 4:30 p.m. ET to provide an update on corporate developments, and to discuss Q1 financial results. Register for free on Stock-Callers.com and download the latest research report on CATB at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA